Publication: Dietary mistletoe lectin supplementation and
reduced growth of a murine non-Hodgkin lymphoma
Authors
Pryme, I.F. ; Bardocz, S. ; Pusztai, A. ; Ewen, S.W.B.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The growth of a murine non-Hodgkin
lymphoma (NHL) tumour has been shown to be reduced
by incorporating mistletoe lectin (ML-1) into the diet.
The morphological characteristics of NHL tumours in
mice fed ML-1-supplemented diets were different from
those in LA (control)-fed mice. The degree of mitotic
activity was lower and nuclear area reduced. The degree
of lymphocyte infiltration was increased in tumours
from ML-1 fed mice and this was accompanied by a
high incidence of apoptotic bodies. Visual observation of
NHL tumours from individuals fed ML-1 diet showed a
poorly developed blood supply in contrast to control-fed
mice. A major reduction in number of blood capillaries
in NHL tumours was confirmed by microscopic
evaluation of tumour sections. The results suggested an
anti-angiogenic response in ML-1-fed mice. The feeding
of ML-1 compared to control diet thus provided several
identifiable changes in the morphology of NHL tumours
which were consistent with the observed reduction in
tumour weight. There was no longer histological
evidence of viable tumour in 25% mice fed the ML-1
diet for 11 days. Morphological studies of the small
bowel indicated (a) that the lectin induces hyperplasia,
and (b) that the lectin binds avidly to lymphoid tissue of
P e y e r’s patches. There was evidence of limited
endocytosis of the lectin. An experiment where ML-3
was added to the diet of mice three days after inoculation
of tumour cells showed that the lectin was able to slow
down further growth of an established tumour. The
results show that ML lectins induce powerful anti-cancer
effects when provided by the oral route.
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.